U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
Investing.com - Cantor Fitzgerald raised its price target on MiMedx Group (NASDAQ:MDXG) to $12.00 from $11.00 on Thursday, while maintaining an Overweight rating on the stock. With the stock currently trading at $6.52, InvestingPro analysis suggests MDXG is undervalued, supported by a "GREAT" overall financial health score of 3.46/5.
The price target increase follows MiMedx’s second-quarter revenue beat and raised 2025 revenue guidance. The company reported revenue of $98.6 million, exceeding both Cantor’s estimate of $91.4 million and the FactSet consensus of $90.4 million.
MiMedx achieved approximately 13% year-over-year growth, driven by its wound portfolio, which increased about 12% year-over-year to $64.5 million. The surgical segment grew approximately 15% year-over-year to $34.1 million.
The company ended the quarter with approximately $100.0 million in net cash, up from roughly $88 million in the first quarter of 2025 and $50 million in the year-ago period. Cantor Fitzgerald noted that MiMedx’s cash generation profile is "underappreciated."
Cantor Fitzgerald believes MiMedx is positioned to gain market share in 2026 and represents an undervalued opportunity, recommending investors buy the stock even on today’s strength.
In other recent news, MiMedx Group Inc reported robust financial results for the second quarter of 2025. The company achieved earnings per share (EPS) of $0.10, which is double the forecasted $0.05. Additionally, MiMedx surpassed revenue expectations, reporting $98.61 million compared to the anticipated $90.62 million. These results indicate strong company performance and have been met with positive investor sentiment. The company’s financial achievements have been noted by analysts, though no specific upgrades or downgrades were mentioned in recent reports. These developments highlight MiMedx’s ability to exceed market expectations in both earnings and revenue. Investors are likely to keep a close watch on the company’s future performance based on these recent results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.